My ePortfolio Register   

PD-1 therapy with eribulin for triple negative MBC

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.12.16
Views: 697
Rating:

Dr Sara Tolaney - Dana–Farber Cancer Institute, Boston, USA

Dr Tolaney speaks with ecancertv at the 2016 San Antonio Breast Cancer Symposium about results from a phase Ib/II study of anti-PD-1 pembrolizumab with eribulin mesylate, a microtubule growth inhibitor, for metastatic breast cancer patients.

She describes the benefits to patients, with a complete and objective responses recorded at this interim analysis, which she notes as being independent of PD-L1 positivity in samples.

Dr Tolaney considers the toxicity profile of checkpoint inhibitory therapy, and the broader future of immunotherapy for breast cancer.

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence